BiotechTube
Sinclair Pharma

Sinclair Pharma

Paris, France· Est.
sinclair.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Sinclair Pharma is an established, commercial-stage player in the global medical aesthetics market, offering a diversified portfolio of injectable dermal fillers (e.g., MaiLi, Perfectha, Ellansé) and energy-based devices (e.g., Cooltech, Primelase). Uniquely positioned as a 'holistic aesthetics' provider, it supports the full patient journey with a science-backed product range sold in over 55 countries. Following its 2018 acquisition by Chinese pharmaceutical giant Huadong Medicine, Sinclair benefits from expanded resources and access to key markets while maintaining its operational focus on innovation and clinician education.

DermatologyAesthetic Medicine

Technology Platform

Portfolio of technologies for injectable dermal fillers (hyaluronic acid, collagen biostimulators) and energy-based devices (laser, cryolipolysis, radiofrequency) for holistic aesthetic treatments.

Funding History

1
IPOUndisclosed

Opportunities

The massive and growing medical aesthetics market, particularly in Asia-Pacific facilitated by parent company Huadong Medicine, presents a major expansion opportunity.
The trend towards holistic, multi-modal treatment plans aligns perfectly with Sinclair's diversified portfolio of injectables and devices, allowing for cross-selling and integrated treatment protocols.

Risk Factors

Intense competition from larger, well-funded global aesthetics companies requires constant innovation and marketing spend.
Geopolitical and trade tensions, as a Chinese-owned company operating globally, could disrupt supply chains or market access.
The business is also susceptible to macroeconomic downturns that reduce discretionary spending on aesthetic procedures.

Competitive Landscape

Sinclair competes in a crowded global market dominated by giants like AbbVie (Allergan Aesthetics), Galderma, and Merz, alongside numerous other device and injectable companies. Its strategy to differentiate focuses on a 'holistic' portfolio and education, but it must continually prove its value against competitors with greater scale and marketing resources.

More companies in Small Molecule Drugs →More companies in France →